FAQs on Biomarkers in Multiple Myeloma

Mary DeRome, Senior Director of Medical Communications and Education at the Multiple Myeloma Research Foundation, gets answers to frequently asked questions on biomarkers in multiple myeloma from Dr. Alexander Lesokhin from Memorial Sloan Kettering Cancer Center, and Dr. Joshua Richter from Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.
Dr. Lesokhin and Dr. Richter provide insights on several topics relating to the use of biomarkers in myeloma management, such as…
· Standard multiple myeloma biomarkers
· Genomics
· Minimal residual disease
· New/emerging biomarkers
This session is supported by 2seventy bio, AbbVie, Adaptive, Baxter, Bristol Myers Squibb, CURE, GSK, Johnson & Johnson, Karyopharm, Pfizer, Regeneron, Sanofi, and Takeda.
If you have questions, call our MMRF Patient Navigation Center at 1-888-841- 6673. To visit the Virtual Exhibit Hall, visit: event.webcasts.com/starthere....

[@kimjohnson325]

Can you tell me what to look for,I have positive CD marks cd3 cd5 cd20 cd79a cd23 and pax5 Bcl2 so what to look for ,I have no cule